Susceptibility of anaerobic bacteria to trovafloxacin: Comparison with other quinolones and non-quinolone antibiotics

Infectious Diseases in Clinical Practice

Volumn 5, Issue SUPPL. 3, 1996, Pages

  Spangler, S K ^a   Jacobs, M R ^b   Appelbaum, P C ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFOXITIN; CIPROFLOXACIN; FLEROXACIN; GREPAFLOXACIN; LOMEFLOXACIN; METRONIDAZOLE; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TAZOBACTAM; TROVAFLOXACIN;

ANAEROBIC BACTERIUM; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; DRUG EFFICACY; HUMAN; MINIMUM INHIBITORY CONCENTRATION;

EID: 0029779722     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019048-199606001-00004     Document Type: Article

References (45)

1. Finegold SM, George WL, editors. Anaerobic infections in humans. New York: Academic Press, 1989.
2. Nord CE. Mechanisms of β-lactam resistance in anaerobic bacteria. Rev Infect Dis 1986; 8 Suppl 5: S543-S548.
3. Appelbaum PC, Spangler SK, Jacobs MR. β-Lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin/clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bactcroides fragilis Bactcroides isolates and 129 fusobacteria from 28 U.S. centers. Antimicrob Agents Chemother 1990;34:1546-50.
4. Jacobs MR, Spangler SK, Appelbaum PC. β-Lactamase production, β-lactam sensitivity and resistance to synergy with clavulanate of 737 Bacteroides fragilis group organisms from thirty-three US centres. J Antimicrob Chemother 1990;26:361-70.
5. Appelbaum PC, Spangler SK, Jacobs MR. Susceptibility of 539 gram-positive and gram-negative anaerobes to new agents, including RP 59500, biapenem, trospectomycin and piperacillin/tazobactam. J Antimicrob Chemother 1993;32:223-31.
6. Appelbaum PC, Spangler SK, Pankuch GA, et al. Characterization of a β-lactamase from Clostridium clostridioforme. J Antimicrob Chemother 1994;33:33-40.
7. Prabhala RH, Rao B, Marshall R, Bansal MB, Thadepalli H. In vitro susceptibility of anaerobic bacteria to ciprofloxacin (Bay o 9867). Antimicrob Agents Chemother 1984;26:785-6.
8. Wise R, Andrews JM, Danks G. In vitro activity of enoxacin (CI-919), a new quinolone derivative, compared with that of other antimicrobial agents. J Antimicrob Chemother 1984;13:237-44.
9. Goldstein EJC, Citron DM. Comparative activity of the quinolones against anaerobic bacteria isolated at community hospitals. Antimicrob Agents Chemother 1985;27: 657-9.
10. Jones BM, Geary I, Lee ME, Duerden BI. Activity of pefloxacin and thirteen other antimicrobial agents in vitro against isolates from hospital and genitourinary infections. J Antimicrob Chemother 1986;17:739-46.
11. Wüst J, Hardegger U. Comparative in vitro activity of cefetamet and fleroxacin against anaerobic bacteria. Eur J Clin Microbiol 1987;6:688-90.
12. Chin N-X, Novelli A, Neu HC. In vitro activity of lome-floxacin (SC-47111; NY-198), a difluoroquinolone 3-carboxylic acid, compared with those of other quinolones. Antimicrob Agents Chemother 1988;32:656-62.
13. Barry AL, Fuchs PC. In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin and fleroxacin. Antimicrob Agents Chemother 1991;35:955-60.
14. Goldstein EJC, Citron DM. Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and Win 57273 against anaerobic bacteria. Antimicrob Agents Chemother 1992;36:1158-62.
15. Bauernfeind, A. Comparative in vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990. J Antimicrob Chemother 1993;31:505-22.
16. Fernandes PB, Shipkowitz N, Bower RR, Jarvis KP, Weisz J, Chu DTW. In vitro and in vivo potency of five new fluoroquinolones against anaerobic bacteria. J Antimicrob Chemother 1986;18:693-701.
17. Venezia RA, Yocum DM, Robbiano EM, Echols RM. Comparative in vitro activities of a new quinolone, Win 57273, and piperacillin plus tazobactam against anaerobic bacteria. Antimicrob Agents Chemother 1990;34:1858-61.
18. Ueno K, Watanabe K, Kato N, Muto Y, Bandoh K, Oka M. OPC-17116, a novel quinolone: in vitro activity against anaerobic bacteria [abstract 1467]. In: Proceedings and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 29-October 2, 1991; Chicago (IL). Washington (DC): American Society for Microbiology, 1991.
19. Finegold SM, Molitoris E, Reeves D, Wexler HM. In vitro activity of temafloxacin against anaerobic bacteria: a comparative study. J Antimicrob Chemother 1991;28 Suppl C: 25-30.
20. Appelbaum PC, Spangler SK, Jacobs MR. Susceptibilities of 394 Bacteriodes fragilis, non-B. fragilis group Bacteroides species, and Fusobacterium species to newer antimicrobial agents. Antimicrob Agents Chemother 1991; 35:1214-8.
21. Wexler HM, Molitoris E, Finegold SM. In vitro activities of three of the newer quinolones against anaerobic bacteria. Antimicrob Agents Chemother 1992;36:239-43.
22. Ueno K, Watanabe K, Kato N, Kalo H, Bandoh K, Tanaka Y. Comparative in vitro activity of AM-1155, a new quinolone, against anaerobic bacteria [abstract 26]. In: Proceedings of the 4th International Symposium on New Quinolones; August 27-29; Munich (Germany): 1992.
23. Fu KP, Lafredo SC, Foleno B, et al. In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin. Antimicrob Agents Chemother 1992;36:860-6.
24. Kato N, Watanabe K, Kato II, Tanaka K, Tanaka Y, Ueno K. Comparative in vitro activity of DU-6859a, a new quinolone, against anaerobic bacteria (abstract 990). In: Proceedings and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy; Oct 17-20, 1993; New Orleans (LA). Washington (DC): American Society for Microbiology, 1993.
25. Appelbaum PC, Spangler SK, Shiman R, Jacobs MR. Susceptibilities of 540 anaerobic gram-negative bacilli to amoxicillin, amoxicillin-BRL 42715, amoxicillin-clavu-lanate, temafloxacin, and clindamycin. Antimicrob Agents Chemother 1992;36:11-40-3.
26. Barry AL, Fuchs PC, Citron DM, Allen SD, Wexler HM. Methods for testing the susceptibility of anaerobic bacteria to two fluoroquinolone compounds, PD 131628 and clinafloxacin. J Antimicrob Chemother 1993;31:893-900.
27. Barrett MS, Jones RN, Erwin ME. In vitro activity of E-4868, a new trifluoroquinolone, compared to six similar compounds. Eur J Clin Microbiol Infect Dis 1993;12:134-41.
28. Guinea J, Robert M, Gargallo-Viola D, et al. In vitro and in vivo antibacterial activities of E-4868, a new fluoroquinolone with a 7-azetidin ring substituent. Antimicrob Agents Chemother 1993;37:868-74.
29. Pankuch GA, Jacobs MR, Appelbaum PC. Susceptibilities of 428 gram-positive and -negative anaerobic bacteria to Bay y 3118 compared with their susceptibilities to ciprofloxacin, clindamycin, metronidazole, piperacillin, piperacillin-tazobactam, and cefoxitin. Antimicrob Agents Chemother 1993;37:1649-54.
30. Yoshida T, Mitsuhashi S. Antibacterial activity of NM 394, the active form of prodrug NM 441, a new quinolone. Antimicrob Agents Chemother 1993;37:793-800.
31. Cooper MA, Andrews JM, Wise R. In vitro activity of tosufloxacin, a new quinolone antibacterial agent. J Antimicrob Chemother 1992;29:639-47.
32. Wexler HM, Molitoris E, Reeves D, Finegold SM. In vitro activity of D U-6859a against anaerobic bacteria. Antimicrob Agents Chemother 1994; 38:2504-9.
33. Gootz TD, Brighty KE, Andersen MR, et al. In vitro activity and synthesis of CP-99,219, a novel 7-(3-azabicyclo [3.1.0] hexyl) naphthyridone [abstract 751]. In: Proceedings and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 11-14, 1992; Anaheim (CA). Washington (DC): American Society for Microbiology, 1992.
34. Jones RN, Erwin ME, Briggs-Gooding B. In vitro antimicrobial activity studies of CP-99,219, a new 7-azabicyclo naphthyridone [abstract 753]. In: Proceedings and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy; October 11-14, 1992; Anaheim (CA). Washington (DC): American Society for Microbiology, 1992.
35. Neu HC, Chin NX. In vitro activity of CP-99,219, 7-(3-azabicyclo [3-1.0] hexyl) naphthyridone [abstract 754]. In: Proceedings and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy; October 11-14, 1992; Anaheim (CA). Washington (DC): American Society for Microbiology, 1992.
36. Gooding BB, Jones RN. In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. Antimicrob Agents Chemother 1993;37:349-53.
37. Girard AE, Faiella JA, Cimochowski CR, Brighty KE. In vivo oral activity of CP-99,219 in models of acute and localized infection [abstract 1510]. In: Proceedings and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy; October 17-20, 1993; New Orleans (LA). Washington (DC): American Society for Microbiology, 1993.
38. Brighty KE, Gootz TD, Girard A, et al. 7-(3-azabicyclo [3.1.0] hexyl) quinolone antibacterial agents: synthesis and biological evaluation resulting in identification of CP 99,219 [abstract 1509]. In: Proceedings and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy; October 17-20, 1993; New Orleans (LA). Washington (DC): American Society for Microbiology, 1993.
39. Eliopoulos GM, Klimm K, Eliopoulos CT, Ferraro MJ, Moellering RC Jr. In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria. Antimicrob Agents Chemother 1993;37:366-70.
40. Gooding BB, Jones RN. In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. Antimicrob Agents Chemother 1993;37:349-53.
41. Jones RN, Erwin ME. In vitro activity of CP-74,667 compared to four other fluoroquinolones. Diagn Microbiol Infect Dis 1992;15:531-6.
42. Spangler SK, Jacobs MR, Appelbaum PC. Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxa-ein, metronidazole, cefoxitin, piperacillin and piperacillin/tazobactam. Antimicrob Agents Chemother 1994;38: 2471-6.
43. Appelbaum PC, Spangler SK, Jacobs MR. Evaluation of two methods for rapid testing for β-lactamase production in Bacteroides and Fusobacterium. Eur J Clin Microbiol Infect Dis 1992;9:47-50.
44. National Committee for Clinical Laboratory Standards. 1993. Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved standard [NCCLS publication no. M11-A31. 3rd ed. Villanova (PA): NCCLS.
45. Teng R, Harris SC, Foulds G, Silber BM, Liston TE. Pharmacokinetics of CP-99,219, a new quinolone antibiotic, following single oral closes to healthy volunteers [abstract 1512]. In: Proceedings and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy; October 17-20, 1993; New Orleans (LA). Washington (DC): American Society for Microbiology, 1993.